A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation
Gregory T. Everson, Norah A. Terrault, Anna S. Lok, Del R. Rodrigo, Robert S. Brown, Sammy Saab, Mitchell L. Shiffman, Abdullah M.S. Al‐Osaimi, Laura M. Kulik, Brenda W. Gillespie, James E. Everhart, and the Adult‐to‐Adult Living Donor Liver Transplantation Cohort Study – 23 July 2012 – Hepatitis C virus (HCV) infection recurs in liver recipients who are viremic at transplantation. We conducted a randomized, controlled trial to test the efficacy and safety of pretransplant pegylated interferon alpha‐2b plus ribavirin (Peg‐IFN‐α2b/RBV) for prevention of post‐transplant HCV recurrence.